乳腺浸润性导管癌中PDGF-BB表达与预后的关系

Relationship between the expression of PDGF-BB and prognosis in breast invasive ductal carcinoma

目的:探讨血小板源性生长因子-BB(PDGF-BB)表达与乳腺浸润性导管癌临床预后的关系。方法:采用免疫组化法检测115例乳腺浸润性导管癌组织PDGF-BB表达,应用卡方检验分析PDGF-BB表达与临床病理特征的关系,Kaplan-Meier法计算中位无瘤生存时间,Log-rank检验比较不同PDGF-BB表达中位无瘤生存时间的差异,采用Cox回归模型进行多因素生存分析。结果:PDGF-BB阳性表达与有无淋巴结转移、肿瘤直径有关(P<0.05);在不同年龄、月经状态、孕激素受体(PR)、雌激素受体(ER)、人类表皮生长因子受体-2(HER-2)状态等临床病理特征上PDGF-BB阳性表达率的差异无统计学意义(P>0.05)。PDGF-BB阳性表达者的中位无瘤生存时间较PDGF-BB阴性表达者短,差异有统计学意义(P<0.05);PDGF-BB阳性表达(HR=3.821,95%CI:1.139~2.810,P=0.030)、发生淋巴结转移(HR=2.708,95%CI:1.129~6.494,P=0.026)、HER-2阳性(HR=3.651,95%CI:1.667~7.999,P=0.001)是乳腺浸润性导管癌预后的独立危险因素,PR阳性(HR=0.437,95%CI:0.209~0.913,P=0.028)、接受化疗(HR=0.150,95%CI:0.040~0.559,P=0.005)是乳腺浸润性导管癌预后的独立保护因素。结论:PDGF-BB表达促进乳腺癌浸润性导管癌进展,是影响预后的独立因素,可以作为乳腺浸润性导管癌预后评估的临床指标。

Objective:To explore the relationship between the expression of platelet-derived growth factor-BB(PDGF-BB)in breast invasive ductal carcinoma and clinical prognosis.Methods:Immunohistochemistry was used to detect the expression of PDGF-BB in 115 cases of breast invasive ductal carcinoma.Chi-square test was employed to analyze the relationship between the expression of PDGF-BB and the clinicopathological characteristics.Kaplan Meier method was used to calculate the median tumor free survival time.Log-rank test was used to compare the difference between the median tumor free survival time and different PDGF-BB expressions.Cox regression model was used to analyze the multifactor survival.Results:The positive expression of PDGF-BB was related to the lymph node metastasis and tumor diameter(P<0.05).There was no significant difference in PDGF-BB positive expression rate in different ages,menstrual status,progesterone receptor(PR),estrogen receptor(ER),human epidemal growth factor receptor-2(HER-2)status(P>0.05).The median tumor free survival time of PDGF-BB positive expression was shorter than that of PDGF-BB negative expression(P<0.05).PDGF-BB positive expression(HR=3.821,95%CI:1.139~2.810,P=0.030),lymph node metastasis(HR=2.708,95%CI:1.129-6.494,P=0.026).HER-2 positive(HR=3.651,95%CI:1.667~7.999,P=0.001)were independent risk factors for prognosis of breast invasive ductal carcinoma,and PR positive(HR=0.437,95%CI:0.209~0.913,P=0.028)and chemotherapy(HR=0.150,95%CI:0.040~0.559,P=0.005)were independent protective factors for prognosis of breast invasive ductal carcinoma.Conclusion:The expression of PDGF-BB can promote the progression of invasive ductal carcinoma of breast,which is an independent factor affecting the prognosis,and can be used as a clinical indicator for the prognosis evaluation of invasive ductal carcinoma of breast.